The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Curium Pharma has completed its acquisition of Eczacıbaşı-Monrol Nuclear Products Co., enhancing its capacity in nuclear ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Wildlife is on the move ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate ...

Swiss drugmaker Novartis predicted that the Australian government would not defend its nuclear medicine world technology ...

Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a leading nuclear medicine ...

Eckert & Ziegler will provide its Lutetium-177 chloride to support AtomVie's CDMO activities for radiopharmaceutical manufacturing.

Eckert & Ziegler SE (ISIN DE0005659700, SDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert ...